AlphAIAlphAI — Financial news for AI agents
tradingview.com$LQDA

LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook

Liquidia (LQDA) reported Q3 2026 earnings of $0.80 per share, beating estimates by $0.03, with revenues of $225.3M, up 314.6% YoY. The company highlighted growth in YUTREPIA demand and commercial stability post-settlement with United Therapeutics. Management expects to provide 2027 revenue outlook in early January.

Original reporting
tradingview.com
Published Nov 11, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 6:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook — source image
Source · tradingview.com
Decision brief

The 30-second read

$LQDABullishMed
01

Why it matters

Earnings beat and removal of litigation risk provide a catalyst for short‑term price appreciation, while guidance for 2027 remains pending.

02

Market read

The earnings surprise and settlement removal are fresh, material news for LQDA, offering a short‑term trading edge.

03

What to watch

Potential payer or formulary pushback could limit upside despite short‑term beat.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Liquidia's Q3 2026 earnings call highlighted product growth, settlement resolution, and upcoming pipeline milestones.

Company-level read

Ticker impact

$LQDABullishHigh confidence
Context

Liquidia reported Q3 earnings beat (EPS 0.80 vs 0.77) and revenue $225.3M vs $186.6M estimate, plus settlement removal and strong product demand.

Expected impact

likely upward pressure as market prices in the earnings beat and settlement resolution

Evidence & confidence

The beat is material and the settlement removes a litigation overhang, both fresh facts that can move the stock.

Market effects

Sector

Positive signal for PAH biotech sector as a competitor clears a legal hurdle.

Regional

U.S. biotech investors may re‑price similar settlement‑risk stocks.

Global

Limited to niche pulmonary hypertension market.

Counterpoint

What could challenge this read

The beat may be already priced; focus on guidance pending and high valuation metrics.

Key entities

  • Company
    Liquidia Corporation

    Biopharma company developing YUTREPIA for PAH.

  • Company
    United Therapeutics

    Settled litigation with Liquidia affecting YUTREPIA market.

Read at source← All news

StoryLiquidia reports Q3 2026 loss after $389.7M settlement with United Therapeutics

Also covered by

4 outlets

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

zacks.com
$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

finance.yahoo.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com
$LQDAMed

BTIG raises Liquidia stock price target to $87 on strong demand

BTIG raised its price target for Liquidia Technologies (LQDA) to $87 from $70, citing strong demand for Yutrepia and increased 2027 EPS estimates. LQDA's Q3 revenue beat expectations at $225.3M, with Yutrepia sales up 31%, though GAAP EPS loss was $2.64 due to a $389.7M settlement charge. Jefferies also raised its target to $62, maintaining a Buy rating.

investing.com